Significantly, the present data highlight cellular mechanisms likely to be involved in the clinical effects of PDE4 inhibitors on the treatment of asthma and COPD [58] and help to explain their role in the prevention of virally trigged exacerbations of asthma and COPD and other viral infection-induced lung conditions. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.